Johnson & Johnson

• 8-KLeadership change

  Filed Aug 4

  Tom Cavanaugh will succeed retiring Jennifer Taubert as Innovative Medicine head and join the Executive Committee.

• 8-KNegativeGuidance loweredImpairment / chargeDeal completed

  Filed Jul 29

  Firefly Bio acquisition and Sail Biomedicines collaboration drive cuts to FY2026 adjusted EPS and operating margin guidance.

• 8-KImpairment / chargeLegal / investigation

  Filed Jul 27

  Proposed ovarian talc settlement hinges on 95% claim participation after court challenged evidence of specific causation.

• 10-QQ2 FY2026RestructuringImpairment / charge

  Filed Jul 23

  Oncology launches, TREMFYA and CAPLYTA outpaced STELARA biosimilar erosion; Orthopaedics separation costs weighed on MedTech margins.

  • Revenue$25.3BYoY +6.6%
  • Net income$5.5BYoY −0.1%

• 8-KPositiveEarningsGuidance raisedRestructuring

  Filed Jul 15

  Oncology and TREMFYA drive Innovative Medicine growth despite STELARA declines; strong operations lift sales and adjusted EPS guidance.

• 8-KShareholder vote

  Filed Apr 27

  Shareholders rejected an independent board chair requirement and elected all director nominees.

• 10-QQ1 FY2026MixedRestructuringImpairment / charge

  Filed Apr 22

  Oncology, CAPLYTA and cardiovascular devices drove growth despite STELARA biosimilar pressure; a prior-year talc reserve reversal skewed earnings.

  • Revenue$24.1BYoY +9.9%
  • Net income$5.2BYoY −52.4%

• 8-KPositiveEarningsGuidance raised

  Filed Apr 14

  Innovative Medicine and MedTech drove sales growth despite STELARA’s drag; FY2026 sales and adjusted EPS guidance raised.

• 10-KFY2025

  Filed Feb 11

  DARZALEX and CARVYKTI growth offset STELARA’s biosimilar-driven decline; a talc reserve reversal boosted earnings without lifting operating cash flow.

  • Revenue$94.2BYoY +6.0%
  • Net income$26.8BYoY +90.6%

• 8-KPositiveEarningsNew guidanceRestructuring

  Filed Jan 21

  Oncology and neuroscience drove drug growth despite STELARA declines; electrophysiology, Abiomed and wound closure lifted MedTech.

Coverage: 10-K filings filed since Feb 11, 2026; 10-Q since Apr 22, 2026; 8-K since Jan 21, 2026.

Request longer coverage

Company data: Wikidata Q333718